







an Open Access Journal by MDPI

Molecular Diagnosis and Treatment of Leukemia

Guest Editor:

Dr. Ancuta Jurj

Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Haţieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania

Deadline for manuscript submissions:

closed (31 December 2020)

Message from the Guest Editor

In the last several decades the field of leukemia has seen important advancements in the diagnosis, classification, and treatment of these patients. One of the first cornerstones in this regard is represented by the discovery that the BCR-ABL fusion is frequently present in chronic myeloid leukemia, and that it can be targeted with single-agent non-chemotherapy represented by imatinib. Since then, this approach has been extended to other leukemia, such as acute myeloid leukemia, acute lymphoblastic leukemia, myeloproliferative neoplasms, and others. At present, most hospitals offer mutational analysis for genes like FLT3, JAK2, CALR, and MPL, to name a few. This has advanced in other hospitals with the existence of comprehensive gene panels that can better assess the prognosis of each patient.

Thus, the current Special Issue will be taking papers assessing the use of a variety of molecular markers in leukemia biology, diagnosis, prognosis, and treatment.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Contact Us